Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis

Table 5

Stability profile of voriconazole ophthalmic solutions containing different viscosity modifiers under room conditions (30°C ± 2°C, 65% RH ± 5% RH).

Formulations	Drug content (%)					pH					𝐾calc (days^−1  × 10^4)	𝑡90 days	Intcalc for 2 years
	0 D	3 W	6 W	3 M	6 M	0 D	3 W	6 W	3 M	6 M
Control	100±0.01	98.00±0.01	97.70±0.02	97.11±0.03	95.12±0.01	7.0	6.9	6.7	6.6	6.3	2.59	404	109.7
XG	100±0.01	99.74±0.01	99.21±0.00	98.90±0.00	97.98±0.00	7.0	7.0	7.0	6.9	6.9	1.13	929	104.2
SCMC	100±0.00	99.73±0.00	99.11±0.00	98.77±0.00	97.31±0.01	7.0	6.9	6.9	6.9	6.9	1.51	694	105.5
Gelrite	100±0.00	99.40±0.00	98.83±0.00	98.58±0.01	97.18±0.01	7.0	6.9	6.9	6.8	6.8	1.58	660	105.8
SA	100±0.00	99.23±0.01	98.74±0.01	98.27±0.01	97.11±0.01	7.0	6.9	6.9	6.8	6.8	1.62	645	106.0
GG	100±0.00	99.10±0.00	98.66±0.01	98.11±0.01	96.97±0.00	7.0	6.9	6.8	6.8	6.8	1.71	616	106.3
CS	100±0.00	99.00±0.00	98.43±0.01	98.10±0.01	96.24±0.00	7.0	6.8	6.8	6.8	6.8	2.12	493	107.8
PVA	100±0.00	98.05±0.01	97.76±0.01	97.48±0.01	95.83±0.00	7.0	6.7	6.7	6.7	6.7	2.36	444	108.7

∗Values are mean of ± SD (𝑛=3); D: days; W: weeks; M: months; 𝐾_calc: calculated first-order degradation rate constant; 𝑡₉₀: time to reach 90% of initial drug concentration; Int_calc: calculated initial drug concentration for shelf life (𝑡₉₀) of 2 years.